Tear Sheet

Print Page   Print Page       E-mail Page   Email Page       RSS Feeds   RSS       E-mail Alerts  Email Alerts       Financial Tear Sheet  Tear Sheet

Tear Sheet

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. 

Press Releases
Date Title
01/14/21 NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine
01/06/21 Alkermes to Present at the 39th Annual J.P. Morgan Healthcare Conference
01/06/21 Alkermes Announces Updates to Executive Leadership Team
12/29/20 FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831
12/10/20 Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment
Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

SEC Filings

Filing date Description

Statement of changes in beneficial ownership of securities

Amendment to a previously filed 4

Report of unscheduled material events or corporate event

Report of unscheduled material events or corporate event

Initial filing by director officer or owner of more than ten percent.